Kanuma

Selected form

Sebelipase Alfa

Method of action: Other Alimentary Tract And Metabolism Products

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kanuma

Kanuma (sebelipase alfa) is a highly specialized, prescription-only medication that is classified as an Enzyme Replacement Therapy (ERT). It is administered for the long-term treatment of patients of all ages who have been diagnosed with Lysosomal Acid Lipase (LAL) deficiency. This condition is a rare, inherited metabolic disorder characterized by the body’s inability to properly break down certain fats (lipids).

Property	Description
Active ingredient	Sebelipase alfa (recombinant human Lysosomal Acid Lipase, rhLAL)
Form	Concentrate for solution for intravenous infusion
Pharmacological class	Hydrolytic Lysosomal Enzyme / Enzyme Replacement Therapy (ERT)
Common use	Treatment of Lysosomal Acid Lipase (LAL) deficiency
Origin	Biologic agent (recombinant DNA technology)

Definition and Pharmacological Classification

Kanuma's active ingredient is Sebelipase alfa, a specific replacement enzyme. It is classified as a hydrolytic lysosomal cholesteryl ester and triacylglycerol–specific enzyme, a designation that highlights its singular function of breaking down specific fat molecules. This pharmacological class is distinct, as it provides a functional copy of the missing enzyme rather than attempting to alter the body's existing biochemical processes with a synthetic compound.

Composition, Form, and Unique Origin

Sebelipase alfa is structurally a recombinant human Lysosomal Acid Lipase (rhLAL), a complex protein produced using recombinant DNA technology. A distinguishing feature of its production is that this biologic agent is purified from the egg white of transgenic Gallus (genetically engineered chickens). The medication is provided as a concentrate for solution for intravenous infusion, a mandatory route of administration that ensures the intact enzyme is delivered directly and efficiently into the systemic circulation.

General Purpose: Conceptual Function

The general purpose of this enzyme replacement is to restore the body’s ability to manage stored fats at the cellular level. In LAL deficiency, the missing LAL enzyme prevents the proper degradation of lipids. Sebelipase alfa replaces this deficient function, enabling the crucial process of hydrolysis within the lysosomes, which breaks down accumulated cholesteryl esters and triglycerides. This action helps correct the underlying metabolic imbalance, preventing the harmful, progressive buildup of these lipids in organs that is characteristic of the disorder.

What side effects are possible with Kanuma?

Possible Side Effects and Safety Information

The official safety documentation for Kanuma (sebelipase alfa) centers on the acute risk of hypersensitivity reactions and common, expected adverse effects, often grouped by system. The most serious concern documented in regulatory labeling is the potential for anaphylaxis and other severe, life-threatening hypersensitivity events, which may occur during the infusion or up to four hours after its completion . These acute reactions have been documented both early in the course of enzyme replacement therapy and after extended duration.

The majority of frequently reported adverse reactions affect the gastrointestinal and respiratory systems, classifying these effects as Very Common or Common in regulatory frequency frameworks.

Frequency Classification	Common Adverse Reactions (Examples)
Very Common (ge 10%)	Headache, Fever (Pyrexia), Diarrhea, Vomiting, Rhinitis, Urticaria
Common (ge 1%)	Constipation, Nausea, Asthenia (weakness), Oropharyngeal pain, Chills

Specific safety considerations are noted for certain populations. Infants six months of age or younger with rapidly progressive disease have a significantly higher documented rate of hypersensitivity events compared to older patients. Furthermore, because sebelipase alfa is produced using transgenic chicken eggs, patients with known systemic hypersensitivity to eggs or egg products require specific risk evaluation. The formation of anti-drug antibodies (ADA) against sebelipase alfa is also reported in the labeling, which is a consideration with the potential for decreased efficacy over time.

Overdose and Emergency Response

Official regulatory documents do not provide a standard description of overdose resulting from excessive dosing of sebelipase alfa. Instead, the official guidance focuses on the emergency management of life-threatening hypersensitivity reactions, including anaphylaxis, which are strictly documented as the primary acute risk associated with the administration.

Documented Overdose Manifestations

Manifestations cited in official labeling that require immediate attention include respiratory symptoms such as dyspnoea or severe respiratory distress, along with systemic effects like tachycardia, hypotension, and skin reactions such as urticaria (hives) or a generalized rash. Regulatory documentation notes that infants may experience a higher incidence of signs consistent with a severe reaction compared to older patients. No specific antidote is cited in the official prescribing information.

Required Emergency Actions

In the event of signs or symptoms consistent with a severe hypersensitivity reaction, the regulatory labeling mandates seeking immediate medical care. If anaphylaxis occurs, the infusion must be immediately discontinued. The required emergency action is the prompt initiation of appropriate medical treatment, including the administration of epinephrine. Supportive measures documented in the labeling may involve temporarily interrupting the infusion, lowering the infusion rate, and the administration of treatments such as antihistamines or corticosteroids. The administration must be conducted in a clinical setting with access to cardiopulmonary resuscitation equipment.

Therapeutic Uses of Kanuma

Kanuma is commonly used to help with the long-term management of Lysosomal Acid Lipase (LAL) deficiency, a condition presenting with systemic or localized discomfort in patients of all ages, including infants, children, and adults. The treatment is generally applied across therapeutic domains where additional symptomatic support is needed to address this inherited disorder.

Intervention for Rapidly Progressive Infantile Disease

The medication is commonly used in conditions characterized by periods of heightened symptoms to help with manifestations in infants, such as growth failure and gastrointestinal symptoms that interfere with daily functioning. The treatment is relevant for easing symptoms linked to functional stress and may assist with maintaining functional stability related to growth and nutrient absorption.

Management of Chronic Liver Disease and Metabolic Imbalance

For children and adults, the therapy is applied in clinical settings that involve acute or unstable symptom patterns related to progressive chronic liver disease. It supports managing indicators of liver-specific functional stress, including elevated liver enzyme markers and excessive fat accumulation. Furthermore, Kanuma is relevant in contexts marked by increased discomfort due to severe dyslipidemia, contributing to easing the overall symptom load.

Quick Fact: Support for Chronic Liver-Related Symptoms Kanuma is commonly used when symptoms linked to organ-specific functional stress are present, such as elevated liver enzyme markers and excessive fat accumulation, helping patients cope more steadily with systemic imbalance.

Regulatory References

European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Kanuma (sebelipase alfa)

This section describes the populations eligible for Kanuma based strictly on official regulatory documentation from agencies like the FDA and EMA.

Eligibility Criteria

Kanuma is indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency, covering all age groups (infants, children, and adults).

Contraindications and Restrictions

The medicine is contraindicated (must not be used) in patients who have experienced a life-threatening allergic reaction (anaphylaxis) to the active substance, sebelipase alfa, where attempts to safely restart treatment were unsuccessful. It is also contraindicated in individuals with a life-threatening allergy to egg or any of the product’s excipients, as the product is manufactured using egg whites.

Population Group	Regulatory Status / Limitation
Pediatric patients < 1 month	Safety and effectiveness are not established
Pregnant women	Use should preferably be avoided due to a lack of human data
Elderly patients (≥ 65)	Safety and efficacy have not been evaluated
Patients with egg allergy	Requires careful consideration of risks and benefits

No adjustments to the regimen are typically recommended for patients with renal or hepatic impairment.

What should I know about interactions with other medicines?

The official interaction profile for sebelipase alfa (Kanuma) is distinct from that of small-molecule drugs, as it is a recombinant human protein (enzyme replacement therapy). Regulatory authorities state that traditional pharmacokinetic drug-drug interactions, such as those mediated by Cytochrome P450 (CYP) enzymes or drug transporters, are not anticipated and no interaction studies have been performed.

Interaction-Related Restrictions

Classification	Restriction and Official Basis
Component Contraindication	Formal restriction against use in patients with a known life-threatening hypersensitivity to egg or egg products (relevant due to the drug’s production process).
Administration Constraint	The solution must not be mixed with other medicinal products in the same infusion, in the absence of compatibility data.

Pharmacodynamic Co-treatment Requirements

While not classical drug interactions, the labels require the availability and potential co-administration of certain substances for safety management:

Emergency Agents: Epinephrine must be readily available during infusion to treat potential life-threatening hypersensitivity reactions, including anaphylaxis.
Supportive Agents: Antihistamines and antipyretics may be used as pre-treatment or for managing less severe infusion-related reactions. Corticosteroids may also be used in this context.

The regulatory profile is structured around these material-based restrictions and pharmacodynamic requirements for infusion support, rather than metabolic or clearance changes.

Mechanism of Action

Kanuma (sebelipase alfa) is a recombinant form of the human enzyme lysosomal acid lipase (LAL). Following intravenous administration, the glycoprotein is selectively recognized by cell surface receptors, which mediate its internalization into the lysosome. This mechanism targets the enzyme to its site of action within the cell. Inside the lysosome, sebelipase alfa functions as an exogenous catalyst, hydrolyzing accumulated cholesteryl esters and triglycerides. The enzyme breaks down these lipid particles into their constituent components: free cholesterol, glycerol, and free fatty acids. This enzymatic cleavage restores the essential catabolic function within the lysosome. The resultant downstream effect is the modulation of lipid concentration in tissues where accumulation occurs, particularly the liver and various reticuloendothelial system macrophages. The systemic physiological consequence is a modification of circulating lipid parameters, including a reduction in plasma cholesteryl esters and triglycerides.

Dosage and Administration Information

How Kanuma is Used: Official Administration Guidelines

Kanuma (sebelipase alfa) is administered as a specialized intravenous (IV) infusion only, providing Enzyme Replacement Therapy (ERT) for long-term use in patients with Lysosomal Acid Lipase (LAL) deficiency. The administration protocol is strictly defined and mandates specialized procedural conditions.

Dosing and Administration Schedule

Administration is required in a supervised clinical setting under the care of a healthcare professional. Dosing is weight-based and follows distinct regimens:

Standard Regimen (Non-Infants): The recommended dose is 1 mg/kg of body weight, administered once every other week. The dose may be escalated to 3 mg/kg if the patient shows a suboptimal clinical response.
Infant Regimen (Rapidly Progressive Disease): Treatment begins at 1 mg/kg or 3 mg/kg of body weight, administered once every week. This weekly frequency addresses the rapid progression observed in this population.

Preparation and Infusion Conditions

Kanuma is supplied as a concentrate that requires dilution with 0.9% Sodium Chloride before infusion. The infusion solution must not be mixed with any other medicinal products in the same container. The infusion is administered over a period of at least 2 hours. A shorter 1-hour infusion may be considered for the 1 mg/kg dose once patient tolerability is confirmed.

Procedural and Population Rules

For patients with renal or hepatic impairment, clinical guidelines indicate no dose adjustment is required. If a dose is missed, it should be administered as soon as feasible, and subsequent doses should then follow the new schedule. The infusion must be delivered using specific equipment, including an in-line, low-protein binding 0.2 micron filter, as part of the mandated administration protocol.

Recent Clinical Evidence

Kanuma (sebelipase alfa) is an enzyme replacement therapy for Lysosomal Acid Lipase Deficiency (LAL-D), a rare genetic disorder leading to the accumulation of lipids in various organs.

Clinical Evidence Overview

Clinical development for Kanuma focused on two distinct patient populations: infants with rapidly progressive LAL-D (Wolman disease) and older children and adults with later-onset LAL-D (Cholesteryl Ester Storage Disease, or CESD).

Infants with Rapidly Progressive LAL-D (Wolman Disease)

An open-label, single-arm study (LAL-CL03) in nine infants with rapidly progressive LAL-D evaluated survival beyond 12 months of age. The results showed that six of the nine treated infants survived past 12 months, which represented a favorable outcome compared to the historical control group, where all patients had died by eight months of age.

Children and Adults (Later-Onset LAL-D)

The Phase 3 ARISE trial (LAL-CL02) was a randomized, double-blind, placebo-controlled study involving 66 children and adults. The primary endpoint for this group was the normalization of alanine aminotransferase (ALT) levels, a key indicator of liver damage. The study demonstrated that patients receiving sebelipase alfa had a statistically significant normalization of ALT levels compared to the placebo group after 20 weeks of treatment.

Secondary endpoints included evaluating the effect on blood lipids. Treatment with Kanuma was also associated with significant reductions in low-density lipoprotein cholesterol (LDL-C) and improvements in other lipid parameters. Longer-term, open-label extension data suggested the sustained reduction of these liver and lipid abnormalities.

Frequently Asked Questions (FAQ)

Common questions about Kanuma (FAQ)

Q: Is Kanuma used for anything besides LAL Deficiency?

According to the official product information, Kanuma (sebelipase alfa) is specifically indicated for the treatment of patients who have been diagnosed with Lysosomal Acid Lipase (LAL) deficiency. Regulatory agencies base their approvals on evidence supporting the safety and effectiveness of the drug for this particular condition.

Q: Is Kanuma a cure for LAL Deficiency?

Regulatory documentation defines Kanuma as a long-term enzyme replacement therapy (ERT) for patients with LAL deficiency, providing the missing enzyme. It works by providing the deficient enzyme, but it is not described as a cure for the underlying genetic condition.

Q: How does Kanuma's mechanism compare to other enzyme treatments?

Kanuma is classified as an Enzyme Replacement Therapy (ERT), which means it replaces a specific enzyme that is missing in the body. Its mechanism involves providing the deficient lysosomal acid lipase enzyme to restore the body’s ability to break down certain fats (lipids).

Q: Is Kanuma the only treatment available for LAL Deficiency?

Kanuma is the first and only Enzyme Replacement Therapy (ERT) approved by the FDA for the underlying cause of LAL deficiency. However, official sources indicate that supportive treatments were historically used for management before this specific ERT became available.

Q: Are there any long-term side effects associated with using Kanuma?

Due to the ultra-rare nature of the disease, long-term follow-up data is naturally limited. Regulatory documents do report that patients may develop anti-drug antibodies (ADA). The formation of these antibodies could potentially decrease the enzyme's effectiveness over an extended period of use.

Q: Can Kanuma interact with common pain relievers or cold medicines?

Official labeling indicates that Kanuma is not expected to interact with other drugs via the common metabolic pathways (such as CYP enzymes). No major or minor drug interactions have been noted in the product information.

Q: Does Kanuma interact with birth control pills?

Kanuma is not expected to interact with other drugs via common metabolic pathways, which includes how hormonal medications are processed. However, official information states that no specific studies have been performed to formally evaluate its interaction with hormonal contraceptives.

Q: Are there any foods or drinks that should be avoided with Kanuma?

Regulatory documents do not list general food or drink restrictions. However, official product information includes a contraindication against using Kanuma in patients with a known life-threatening hypersensitivity to egg or egg products. This is due to the drug’s active ingredient being produced using transgenic chicken eggs.

Q: How soon after starting Kanuma can changes in blood fats (lipids) be seen?

Clinical trial data indicates that changes in blood lipid levels, such as the reduction of fat molecules, were observed within 8 weeks of the start of treatment. This finding was documented in studies involving patients with later-onset LAL deficiency.

Q: Does Kanuma improve symptoms immediately, or does it take a long time?

Kanuma is a long-term enzyme replacement therapy intended for sustained use. Measurable changes, such as the normalization of liver enzymes and improvements in blood lipid levels, are assessed over weeks or months. For example, major clinical trials used an endpoint of 20 weeks to evaluate treatment effectiveness.

Q: What kind of research is still being done on Kanuma?

Follow-up research, including long-term extension studies, has been conducted to track the sustained effects and safety profile of Kanuma over an extended duration of treatment. This data collection allows researchers to monitor the long-term status of patients.

Q: How is Kanuma different from other enzyme replacement therapies I’ve heard about?

Kanuma is distinct because it is designed to replace the specific Lysosomal Acid Lipase (LAL) enzyme missing in patients with LAL deficiency. Its active ingredient is uniquely purified from the egg whites of genetically engineered chickens.

Q: Why is LAL Deficiency considered a life-threatening disease?

The condition is described as life-threatening because the accumulation of fats (lipids) in the body's cells leads to severe, progressive complications. This can include rapid liver fibrosis, liver failure, and increased risk of premature cardiovascular disease.

Q: Can Kanuma be used with other treatments for LAL Deficiency symptoms?

Kanuma is a disease-specific enzyme replacement therapy. Patients with LAL deficiency have historically been managed using additional supportive therapies, such as those aimed at reducing high cholesterol levels and managing other symptoms.

How should Kanuma be stored and disposed of?

The storage and disposal of Kanuma (sebelipase alfa) must adhere strictly to regulatory conditions to maintain product stability and safety.

Condition	Regulatory Requirement
Unopened Vials Storage	Refrigerate between 2 C and 8 C (36 F and 46 F). Do not freeze or shake [Source 1.2, 3.1].
Light Protection	Store vials in the original carton to protect the medicinal product from light [Source 1.2, 1.4].
Diluted Solution Stability	Use immediately after dilution due to lack of preservatives. May be stored refrigerated for a maximum of 24 hours at 2 C to 8 C [Source 1.2, 3.1].
Disposal	Vials are for single-use only; discard any unused product [Source 1.2, 3.1]. Disposal must be carried out according to local regulations [Source 1.2, 4.4].

All medicinal products, including Kanuma, must be stored out of the sight and reach of children [Source 1.2]. These rules ensure the integrity of the specialized enzyme replacement therapy and mandate that all unused portions are properly discarded through official local pharmaceutical waste procedures [Source 4.4].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.